Literature DB >> 29370350

Long-term Use of Tedizolid as Suppressive Therapy for Recurrent Methicillin-Resistant Staphylococcus aureus Graft Infection.

Masayuki Nigo1, Andrea M Luce2, Cesar A Arias1,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29370350      PMCID： PMC6248592          DOI： 10.1093/cid/ciy041

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

1.  Thrombocytopenia with Tedizolid and Linezolid.

Authors:  Erica Yookyung Lee; Aisling R Caffrey
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.

Authors:  Gregory J Moran; Edward Fang; G Ralph Corey; Anita F Das; Carisa De Anda; Philippe Prokocimer
Journal:  Lancet Infect Dis       Date:  2014-06-05       Impact factor: 25.071

3.  Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.

Authors:  P Prokocimer; P Bien; J Surber; P Mehra; C DeAnda; J B Bulitta; G R Corey
Journal:  Antimicrob Agents Chemother       Date:  2010-11-29       Impact factor: 5.191

4.  Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.

Authors:  Philippe Prokocimer; Carisa De Anda; Edward Fang; Purvi Mehra; Anita Das
Journal:  JAMA       Date:  2013-02-13       Impact factor: 56.272

5.  Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.

Authors:  Thomas P Lodise; Monique R Bidell; Shawn D Flanagan; Evan J Zasowski; Sonia L Minassian; Philippe Prokocimer
Journal:  J Antimicrob Chemother       Date:  2016-06-17       Impact factor: 5.790
  5 in total
  8 in total

1.  Long-term use of liposomal nebulized amikacin and tedizolid for the treatment of disseminated nocardiosis after allogeneic hematopoietic stem cell transplantation.

Authors:  Sarah Soueges; Claire Triffault-Fillit; Sandrine Roux; Hélène Labussière-Wallet; David Lebeaux; Oana Dumitrescu; Isabelle Morelec; Elisabeth Hodille; Florence Ader
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-03-10       Impact factor: 3.267

2.  Neurological and Psychiatric Adverse Effects of Antimicrobials.

Authors:  Madison K Bangert; Rodrigo Hasbun
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

3.  Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success.

Authors:  Taylor Morrisette; Kyle C Molina; Beatriz Da Silva; Scott W Mueller; Laura Damioli; Martin Krsak; Matthew A Miller; Douglas N Fish
Journal:  Open Forum Infect Dis       Date:  2022-05-23       Impact factor: 4.423

4.  Arthroscopic "Debridement and Implant Retention" With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection.

Authors:  Tristan Ferry; Cécile Batailler; Aubin Souche; Cara Cassino; Christian Chidiac; Thomas Perpoint; Claire le Corvaisier; Jérôme Josse; Romain Gaillard; Julien Roger; Camille Kolenda; Sébastien Lustig; Frédéric Laurent
Journal:  Front Med (Lausanne)       Date:  2021-05-14

Review 5.  Mycobacterium abscessus: Shapeshifter of the Mycobacterial World.

Authors:  Keenan Ryan; Thomas F Byrd
Journal:  Front Microbiol       Date:  2018-11-01       Impact factor: 5.640

Review 6.  MDR Tuberculosis Treatment.

Authors:  Juan Espinosa-Pereiro; Adrian Sánchez-Montalvá; Maria Luisa Aznar; Maria Espiau
Journal:  Medicina (Kaunas)       Date:  2022-01-26       Impact factor: 2.430

Review 7.  Pharmacokinetics and Pharmacodynamics of Tedizolid.

Authors:  Khalid Iqbal; Aliki Milioudi; Sebastian Georg Wicha
Journal:  Clin Pharmacokinet       Date:  2022-02-07       Impact factor: 6.447

8.  Correction of Linezolid-Induced Myelotoxicity After Switch to Tedizolid in a Patient Requiring Suppressive Antimicrobial Therapy for Multidrug-Resistant Staphylococcus epidermidis Prosthetic-Joint Infection.

Authors:  Tristan Ferry; Cécile Batailler; Anne Conrad; Claire Triffault-Fillit; Frédéric Laurent; Florent Valour; Christian Chidiac
Journal:  Open Forum Infect Dis       Date:  2018-09-25       Impact factor: 3.835
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.